Page Contents

Key Performance Indicators

Access to Medicines

Global programs and commercial transactions to increase access to medicines in emerging markets1
2015
19
2016
18
2017
17
2018
17
2019
15
Top 21 global burdens of disease addressed by products and pipeline2
2015
18
2016
19
2017
19
2018
16
2019
16


Overview3

  • We currently have 290 active programs for launched medicines in markets that have a gross domestic product (GDP) per capita less than Portugal.
  • This covers 52 countries.
  • Of these, 20 programs cover multiple therapies while the rest are product specific.
  • In total, these cover 103 different products in our portfolio.
Access to Medicines Footnotes
1.

Program/commercial transaction defined as a Pfizer or dedicated contract of over $250,000 with a national government or procurement agency, multilateral organization, non-governmental organization (NGO), private institution or aid agency. Represents multi-country initiatives only and does not include numerous local initiatives to address access.
2.

Pfizer Foundation programs represent aggregate investment in program areas with several NGO partners.
3.

As defined by the World Health Organization. Burdens of illness not addressed include road traffic accidents, prematurity and low birth weight and self-inflicted injuries.

Top Ten Medicines and Vaccines by Revenues in 2019

1.
$5,847 million

Prevnar® 13 / Prevenar® 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])

2.
$4,961 million

Ibrance® (palbociclib)

3.
$4,220 million

Eliquis® (apixaban)*

4.
$3,321 million

Lyrica® (pregabalin)

5.
$2,242 million

Xeljanz® (tofacitinib)

6.
$1,973 million

Lipitor® (atorvastatin)

7.
$1,699 million

Enbrel® (etanercept)

8.
$1,107 million

Chantix®/Champix® (varenicline)

9.
$950 million

Norvasc® (amlodipine besylate)

10.
$936 million

Sutent® (sunitinib malate)

Top Ten Medicines and Vaccines by Revenues in 2019 Footnote
*Eliquis includes alliance revenues from (Bristol-Myers Squibb) and direct sales.

Colleagues1

Injuries Per 100 Colleagues

Total injury rate in 2019 was 13% lower than in 2018

2016
0.39
2017
0.59
2018
0.45
2019
0.39

Progress on Our 2020 Environmental Sustainability Goals2

Greenhouse Gas (GHG) Emissions

Total scope 1 and 2 GHG emissions

In million metric tons CO2EQ

GHG emissions in 2019 were 5% lower than in 2018



2020 Goals vs Baseline

Decrease by 20%

2012
2.05
2016
1.65
2017
1.56
2018
1.58
2019
1.50
Baseline
Waste Disposed
Total hazardous and non-hazardous waste in thousand metric tons

Total waste disposed in 2019 was 9% higher than in 2018


2020 Goals vs Baseline:
Decrease by 15%

2012
121.56
2016
101.28
2017
94.94
2018
94.10
2019
102.40
Baseline
Water Withdrawal
Excluding non-contact cooling water in million cubic meters

Total water withdrawal (excluding non-contact cooling water) in 2019 was 3% lower than in 2018


2020 Goals vs Baseline:
Decrease by 5%

2012
17.82
2016
15.83
2017
14.76
2018
15.51
2019
15.05
Baseline

Supply Chain Environmental Sustainability Goal3

  2020 Goal 2019 2018 2017
Key suppliers supporting Pfizer's supplier code of conduct 100% 90% 88% 79%
Key suppliers aligning with Pharmaceutical Supply Chain Initiative (PSCI) principles 100% 90% 88% 81%
Key suppliers managing their environmental impacts 100% 88% 84% 82%
Key suppliers with reduction goals for GHG, waste disposal and water withdrawal 90% 49% 52% 41%
KPI Footnotes
1.

Two serious incidents occurred during work related travel in 2019 that tragically resulted in the deaths of two colleagues. The primary causes of injuries and illnesses recorded in 2019 were ergonomics and slips, trips and falls.
2.

Applies to facilities within Pfizer's operational control as compared with a 2012 baseline. Data are baseline adjusted, reported absolute, using reporting boundaries per theWRI GHG Protocol. The 2012–2018 GHG data were independently verified to the limited assurance level. The verification of the 2019 GHG data will be completed in 2020. While we are on track to exceed our GHG emissions and water goals in 2020 and continue to identify and implement resource reduction projects, we anticipate that we will be unable to sustain achievement of our waste reduction goal due to site expansions and increased production. Through 2020 and beyond we will continue to focus on emission and resource reduction projects. Find more details on our EHS KPIshere.

3.

Key suppliers include 115 major contributors to our external environmental footprint, including suppliers of pharmaceutical ingredients, drug products, raw materials, product packaging services, key research and development collaborators, and freight forwarders. Key suppliers represent only a portion of Pfizer’s overall supply chain for goods and services. Data have been adjusted to reflect the transition of our Consumer Healthcare business.